Neurocrine Biosciences (NASDAQ:NBIX) Reaches New 1-Year High Following Analyst Upgrade

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) reached a new 52-week high during mid-day trading on Thursday after JPMorgan Chase & Co. raised their price target on the stock from $148.00 to $158.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. Neurocrine Biosciences traded as high as $148.37 […]

Leave a Reply

Your email address will not be published.

Previous post NVIDIA (NASDAQ:NVDA) Shares Up 1.3% on Analyst Upgrade
Next post Lincoln National (NYSE:LNC) Sets New 12-Month High After Analyst Upgrade